Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Hydrogel-Based Delivery for Antineoplastic Drugs and Vascular Scaffolding

Version 1 : Received: 5 September 2021 / Approved: 6 September 2021 / Online: 6 September 2021 (14:01:12 CEST)

How to cite: Iervolino, A.; Chello, C.; Chello, M.; Nappi, F. Hydrogel-Based Delivery for Antineoplastic Drugs and Vascular Scaffolding. Preprints 2021, 2021090104 (doi: 10.20944/preprints202109.0104.v1). Iervolino, A.; Chello, C.; Chello, M.; Nappi, F. Hydrogel-Based Delivery for Antineoplastic Drugs and Vascular Scaffolding. Preprints 2021, 2021090104 (doi: 10.20944/preprints202109.0104.v1).

Abstract

Hydrogels, hydrophilic polymeric compounds, have been recently put under investigation as regenerative medicine applications and delivery systems for antineoplastic drugs, particularly chemotherapeutics (anthracyclines, alkylating agents), target drugs (trastuzumab) and immunotherapies. Porosity, conductivity, biodegradability and physical states are some of the peculiarities that render hydrogels suitable for therapies implementation. Chemically-modifying agents and enzymes can be also coupled to hydrogels for pharmacokinetical parameters improvement and side effects avoidance. Cardiotoxicity is in fact one of the major issues for oncological patients after treatment efficacy. Heart failure, myocarditis and hypertension are causes of morbidity and mortality that can possibly be avoided. Specific reaching of the target tumor site has been achieved by several authors in preclinical in vivo studies but clinical studies are currently under design processes. Polydioxanone, a hydrogel-mimicking agent, is capable to interact with the elastic properties of pulmonary artery. An advantageous characteristic is that can be also reabsorbed within biological systems and can cause a remodeling process of the vessel wall. Hydrogels currently represent a strong topic of interest for researchers and probably will guide future clinical investigations and practice.

Keywords

hyrogel; cardiotoxicity; regenerative medicine; antineoplastic drugs; polydioxanone; pulmonary autograft

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.